Sumary of FDA clears IND application for T-cell receptor therapy to treat epithelial cancers:
- These include gastrointestinal, lung, cervical and triple-negative breast cancers.
- “TCR T-cell therapy is a promising new treatment modality that has demonstrated clinical activity in a subset of solid tumors,” Norberg said in a T-Cure-issued press release.
- “Our hope is that KK-LC-1 TCR-T cell therapy can be effective against common epithelial cancers, which account for 80% to 90% of all human malignancies.
- “We are excited that NCI has obtained the regulatory approval from FDA to initiate a first-in-human trial against a very important target in multiple solid tumors,” Gang Zeng, PhD, CEO of T-Cure, said in the release.